Aldeyra Therapeutics (ALDX) Research & Development (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Research & Development came in at $2.4 million in Q1 2026, down 67.54% YoY from $7.4 million in Q1 2025, and down 44.01% on a QoQ basis from $4.3 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Research & Development (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Research & Development data on file, last reported at $2.4 million in Q1 2026.
- Quarterly Research & Development fell 67.54% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.6 million (down 58.25% YoY) and the FY2025 annual result came in at $25.7 million, down 46.78% from the prior year.
- Research & Development fell to $2.4 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $15.0 million in Q2 2024 to a low of $2.4 million in Q1 2026.
- A 5-year average of $9.0 million and a median of $8.5 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development jumped 240.37% — and 2025, when it sank 70.58%.
- Tracing ALDX's Research & Development over 5 years: stood at $9.0 million in 2022, then plunged by 52.04% to $4.3 million in 2023, then jumped by 240.37% to $14.6 million in 2024, then slumped by 70.58% to $4.3 million in 2025, then slumped by 44.01% to $2.4 million in 2026.
- The last three Research & Development figures came in at $2.4 million (Q1 2026), $4.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | 3.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.48 Mn |
| Mar 31, 2026 | 2.41 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | 8.51 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Dec 31, 2024 | 14.63 Mn |
| Sep 30, 2024 | 12.44 Mn |
| Jun 30, 2024 | 14.97 Mn |
| Mar 31, 2024 | 6.18 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 6.96 Mn |
| Jun 30, 2023 | 6.96 Mn |
| Mar 31, 2023 | 11.24 Mn |
| Dec 31, 2022 | 8.96 Mn |
| Sep 30, 2022 | 11.54 Mn |
| Jun 30, 2022 | 14.57 Mn |
| Mar 31, 2022 | 12.23 Mn |
| Dec 31, 2021 | 12.84 Mn |
| Sep 30, 2021 | 12.89 Mn |